title: [A case of SIADH developed during neoadjuvant chemotherapy using nedaplatin and 5-fluorouracil in a patient with esophageal cancer].
abstract: A 77-year-old male with thoracic esophageal cancer (cT3N3M0, Stage III) received nedaplatin at 80mg/m2 for 1 day and 5-fluorouracil at 800mg/m2 for 5 days as neoadjuvant treatment. On the fifth day of treatment, he lapsed into a coma (Japan Coma Scale 30), and his serum sodium concentration was found to be decreased to 116mEq/L. We concluded hyponatremia due to SIADH (syndrome of inappropriate secretion of antidiuretic hormone) induced by chemotherapy based on the fact that the patient had no finding of dehydration, particular history of related disorders, serum hypoosmolality accompanied by urine hyperosmolality and persistent urinary sodium excretion. We treated him with fluid restriction, sodium supplement and administration of loop diuretic. Then he regained consciousness and appropriate serum sodium level. Thereafter, hyponatremia was corrected without recurrence, and the patient underwent radical esophagectomy safely. He has been in good condition without recurrence of esophageal cancer after surgery.
authors.affiliation: Dept. of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Japan.
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Matsuda
authors.forename: Shigeru
authors.initials: S
authors.lastname: Lee
authors.forename: Satoru
authors.initials: S
authors.lastname: Kishida
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Mori
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Isohata
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Iwasaki
authors.forename: Ryoya
authors.initials: R
authors.lastname: Hashiba
authors.forename: Ken
authors.initials: K
authors.lastname: Gyobu
authors.forename: Harushi
authors.initials: H
authors.lastname: Osugi
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001706:Biopsy; D004938:Esophageal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007177:Inappropriate ADH Syndrome / Q000139:chemically induced*; D008297:Male; D020360:Neoadjuvant Therapy / Q000009:adverse effects*; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed
chemical_list: D009944:Organoplatinum Compounds; C053989:nedaplatin; D005472:Fluorouracil